VRAX

Virax Biolabs Group Limited

Sağlık

COMPLIANT — All screening ratios are below the thresholds; the company is compliant with halal investment criteria.

$0.67

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0.6 / %30

Non-compliant assets / Total market cap %0 / %30

Non-compliant revenue / Total income %0 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.

Website

Analysis (Turkish): VRAX Hissesi Caiz mi, Helal mi? Virax Biolabs Group Limited Katılım Analizi